Trypanosoma brucei is a parasitic protozoan that causes African trypanosomiasis, a potentially fatal disease in humans and animals. The parasite has a complex life cycle that involves multiple morphological and antigenic variations, which allow it to evade the host’s immune system and cause persistent infections.

Immunodominant antigen and variant-specific antigen are two of the most important antigenic components of T. brucei. Immunodominant antigen is a highly conserved protein that is recognized by the host’s immune system, while variant-specific antigen is a highly variable protein that undergoes frequent antigenic variation to evade the host’s immune response. Antigens 6 and 4 are two important immunodominant antigens that have been extensively studied for their diagnostic and immunological properties.

Another important antigenic component of T. brucei is the variant surface glycoprotein MITAT 1.2 (VSG 221), which is a major component of the parasite’s surface coat. VSG 221 is highly variable and undergoes frequent antigenic variation, which allows the parasite to evade the host’s immune system.

Antigen GM6 is another important immunodominant antigen of T. brucei, which has been shown to be highly specific and sensitive in diagnosing African trypanosomiasis. The p21 antigen protein is another important antigenic component that is expressed in the bloodstream stage of the parasite’s life cycle.

DAL972 is a T. brucei strain that is commonly used for experimental studies of the parasite’s biology and pathogenesis. Two important antigenic components of this strain are the proliferating cell nuclear antigen and the calpain-like cysteine peptidase.

Finally, the rhodesiense Variant surface glycoprotein 7 is another important antigenic component of T. brucei, which is specific to the Rhodesian strain of the parasite. Like other variant surface glycoproteins, VSG 7 undergoes frequent antigenic variation to evade the host’s immune system.

Understanding the antigenic properties of T. brucei is crucial for the development of effective diagnostic and therapeutic strategies for African trypanosomiasis. The above-mentioned antigens are some of the key components that play important roles in the biology and pathogenesis of this deadly parasitic disease.

Trypanosoma brucei cDNA and recombinant antigens can be used to develop vaccines that can provide immunity to the disease caused by the parasite. The cDNA can also be used to produce recombinant proteins for diagnostic tests to detect infection. Recombinant antigens can also be used to develop diagnostic tests to detect the presence of the parasite in infected individuals. Additionally, the cDNA can be used to generate transgenic animals that can be used to study the pathogenesis and treatment of the disease.

The use of recombinant proteins/cDNA in academic research and therapeutic applications has skyrocketed. However, in heterologous expression systems, successful recombinant protein expression is dependent on a variety of factors, including codon preference, RNA secondary structure, and GC content. When compared to pre-optimization, more and more experimental results demonstrated that the expression level was dramatically increased, ranging from two to hundred times depending on the gene. Bioclone has created a proprietary technology platform that has resulted in the creation of over 6,000 artificially synthesized codon-optimized cDNA clones (cloned in E. coli expression Vector), which are ready for production of the recombinant proteins.